Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatment
- PMID: 14754599
Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatment
Comment on
-
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.Haematologica. 2004 Jan;89(1):49-57. Haematologica. 2004. PMID: 14754606
Publication types
MeSH terms
LinkOut - more resources
Medical